Previous Article | Next Article 
Infection and Immunity, March 2000, p. 1142-1149, Vol. 68, No. 3
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Modulation of Cytokine Profiles by the Mycoplasma Superantigen
Mycoplasma arthritidis Mitogen Parallels Susceptibility
to Arthritis Induced by M. arthritidis
Hong-Hua
Mu,*
Allen
D.
Sawitzke, and
Barry C.
Cole*
Division of Rheumatology, Department of
Internal Medicine, University of Utah School of Medicine, Salt Lake
City, Utah 84132
Received 20 August 1999/Returned for modification 3 November
1999/Accepted 30 November 1999
 |
ABSTRACT |
Mycoplasma arthritidis mitogen (MAM) is a potent
superantigen secreted by M. arthritidis, an agent of murine
arthritis. Here we compare the abilities of MAM to induce a panel of
cytokines in vitro and in vivo in BALB/c and C3H/HeJ mouse strains that differ in susceptibility to mycoplasmal arthritis. Splenocytes from
both mouse strains produced high levels of all cytokines by 24 h
following in vitro exposure to MAM. No differences in cytokine profiles
were seen irrespective of the MAM dose. However, there were striking
differences in cytokine profiles present in supernatants of splenocytes
that had been collected from mice after intravenous (i.v.) injection of
MAM and subsequently rechallenged with MAM in vitro. Splenocytes
collected 24 and 72 h after i.v. injection of MAM and challenged
in vitro with MAM showed the most marked divergence in the secreted
cytokines. Type 1 cytokines were markedly elevated in C3H/HeJ cell
supernatants, whereas they were depressed or remained low in BALB/c
cell supernatants. In contrast, the levels of type 2 cytokines were all
greatly increased in BALB/c cell cultures but were decreased or
remained low in C3H/HeJ supernatants. Interleukin-12 mRNA and protein
was also markedly elevated in C3H/HeJ mice, as were the levels of
immunoglobulin G2a. The data indicate a major skewing in cytokine
profiles to a type 1 inflammatory response in C3H/HeJ mice but to a
protective type 2 response in BALB/c mice. These cytokine changes
appear to be associated with the severe arthritis in C3H/HeJ mice
following injection of M. arthritidis in comparison to the
mild disease seen in injected BALB/c mice.
 |
INTRODUCTION |
Superantigens (SAgs) are a unique
class of potent immunoregulatory molecules that are produced by
bacteria, viruses, and mycoplasmas (1, 5, 13, 36, 63, 70).
They are presented directly to T cells in association with various
class II major histocompatibility complex molecules on accessory cell
surfaces, usually without the need for processing (8, 22,
27), and are recognized predominantly by T cells bearing specific
V
chain segments of the T-cell receptor for antigen (TCR) (31,
34, 41). Since recognition is dependent upon fewer restricting
elements than are required for traditional antigens, large numbers of
naive T cells may be activated. This response contributes to the marked inflammation seen after in vivo administration of SAgs, which has clear
implications for disease pathogenesis.
The Mycoplasma arthritidis-derived SAg, M. arthritidis mitogen (MAM), is secreted by an organism
(11) that spontaneously or experimentally can induce acute
and chronic forms of arthritis in rodents (18). MAM is in
many respects a typical SAg (9), although it is
phylogenetically unrelated to other known bacterial or viral SAgs
(14). However, as for selected other SAgs (48), bridging between B cells and T cells can also lead to B-cell
differentiation (20), and MAM can also directly activate
macrophages and natural killer (NK) cells (3, 23, 24, 53).
MAM also has a number of other unique features that differentiate it
from other bacterial SAgs, including its strong preference for H-2E
or HLA-DR
molecules rather than H-2A or HLA-DQ for presentation to T
cells (10). It was recently shown that MAM, unlike other
bacterial SAgs, also has contact points with the third
complementarity-determining region (CDR3) of the TCR (32).
Another major difference is that in proliferation assays MAM is
103- to 104-fold more effective for murine
cells than are the staphylococcal SAgs in respect to the doses
required to induce maximal lymphocyte proliferation (15).
Cytokine profiles elicited by microorganisms and their products play a
key role in disease expression in their natural hosts. The exposure of
a normal host to an infectious agent ultimately results in the
acquisition of protective immunity or immunopathology. Cytokines
represent the principal regulators of the immune system. The
preferential activation and expansion of CD4+ T cells
producing a restricted set of cytokines allow their subdivision into
two major subsets: Th1 and Th2 cells (26, 46, 47). Th1
cells, which secrete interleukin-2 (IL-2), gamma interferon (IFN-
)
and tumor necrosis factor alpha (TNF-
), are responsible for
phagocyte-dependent protective immunity and tissue injury in many
organ-specific autoimmune diseases. Th2 cells, which produce IL-4,
IL-5, IL-10, and IL-13, are involved in the development of allergies
and in defense against helminthic parasites. IL-6 is one of the
earliest factors that trigger the differentiation of naive T cells into
effector Th2 cells in vitro (51). Individual CD4+ T cells which may exhibit complex and quite
heterogeneous patterns of cytokine production but are not
characteristic of either subset have been classified as Th0 cells
(35).
Cytokine responses that resemble Th1 or Th2 responses, but are not
necessarily made by CD4+ T cells, are referred to as type 1 or type 2 cell-mediated immune responses, respectively. Indeed, this is
a more diverse set of effector mechanisms, consisting of a large
variety of cell types, including antigen-activated macrophages,
IFN-
/
-activated NK cells, cytolytic CD8+ T cells, and
neutralizing antibodies (often with Th1 isotype patterns). Both IL-10
and IL-4 are strong inhibitors of IFN-
synthesis, and conversely,
IFN-
inhibits IL-10 production. This may in part explain why
cell-mediated and humoral immune responses are ultimately often
observed to be mutually exclusive.
IL-12 is a heterodimeric cytokine, composed of two subunits (p40 and
p35), which is produced predominantly by activated
monocytes/macrophages, B cells, and other accessory cell types, causes
the induction of IFN-
synthesis as well as augmentation of NK cell
cytotoxicity and cytotoxic T-cell proliferation and function. Most
importantly, IL-12 induces the development of Th1 cells in vitro and in
vivo. IL-12 production is induced by many microbial products, including lipopolysaccharide (LPS) and lipoproteins. IL-12 is therefore a major
modulator of inflammation and immune responses and is likely to play a
significant role in the pathogenesis of infectious and autoimmune
diseases (65).
Evidence has been obtained that lethal toxicity and dermal necrosis
induced by live M. arthritidis may be influenced by MAM. Thus, inbred and congenic mice whose splenocytes are strongly activated
by MAM are susceptible to these conditions, whereas mice whose
lymphocytes are poorly reactive with MAM are resistant. The degree of
reactivity to MAM was largely dependent upon expression of a functional
H-2E major histocompatibility complex molecule which is preferentially
used by MAM for presentation to T cells. However, the association of
reactivity to MAM in vitro and susceptibility to arthritis was less
clear, since high reactivity to MAM did not necessarily predict high
susceptibility to arthritis (16).
Previous work by us had demonstrated that the intravenous (i.v.)
injection of MAM into the BALB/c mouse, a strain that was fairly
resistant to arthritis (17) but highly responsive to MAM in
vitro, resulted in inhibition of lymphocyte proliferation in vivo
(19). This anergic response was restricted to T cells bearing MAM-reactive V
chain segments but could be transferred to
cells from naive mice by a CD4+, CD8
subset
of lymphocytes (19). We also showed that MAM reduced the
ability of splenocytes to secrete IL-2 in response to rechallenge with
MAM but increased the production of IL-4 and IL-6. Work with other
bacterial SAgs, which has also largely been conducted using the
BALB/c mouse strain, has resulted in similar findings and has led to
the belief that SAgs characteristically lead to a state of anergy
following administration in vivo to mice and direct the cytokine
profile toward a type 2 response (28).
In the present communication, we tested the cytokine profiles in
response to MAM in vitro and in vivo in mouse strains that differ in
their susceptibility to the arthritogenic effects of M. arthritidis. Whereas the arthritis-resistant BALB/c mouse, whose
lymphocytes are highly activated by MAM in vitro, elicits a type 2 cytokine profile in response to rechallenge with MAM in vivo, the
C3H/HeJ mouse, which is susceptible to mycoplasmal arthritis
(16), produces overexpression of IL-12 and a type 1 inflammatory response to MAM in vivo. Thus, MAM elicits different cytokine profiles in different strains of mice, and these profiles may
predict susceptibility to mycoplasma-induced disease.
 |
MATERIALS AND METHODS |
Mice.
Female BALB/c (H-2d, H-2 E
+) and
C3H/HeJ (H-2k, H-2 E
+) mice were obtained from Jackson
Laboratory (Bar Harbor, Maine). All mice were maintained under
specific-pathogen-free conditions at the Animal Resource Center of the
University of Utah Health Science Center and were used at 8 to 12 weeks
of age. The Animal Resource Center guarantees strict compliance with
regulations established by the Animal Welfare Act.
MAM.
Native MAM (nMAM) was prepared as described previously
(4). nMAM was electrophoretically homogeneous, and the
leading and trailing edges of the collected peak after alkyl Superose
chromatography exhibited identical N-terminal sequences by Edman
degradation and showed no signs of other proteins. M. arthritidis does not contain LPS (61), and the nMAM
preparations used in this study failed to induce lymphocyte
proliferation in splenocytes from LPS-reactive but non-MAM-reactive SJL
mice (H-2s). Similarly, nMAM failed to induce any cytokine
activity in SJL splenocyte cultures in vitro (15) or in SJL
mice (H.-H. Mu, A. D. Sawitzke, and B. C. Cole, unpublished
observations), thus confirming the absence of LPS.
Cell culture and induction of cytokines.
Single cell
suspensions of lymphoid cells were prepared from pooled spleens of at
least three mice. Erythrocytes in the single cell suspensions were
lysed by brief treatment with sterile 0.83% (wt/vol) ammonium chloride
solution. Subsequently, the cells were washed three times and
resuspended at a density of 107 cells/ml in 24-well plates
(Corning Class Works, Corning, N.Y.). The culture medium consisted of
RPMI 1640 supplemented with 1% Nutridoma-NS (Boehringer Mannheim
Biochemicals, Indianapolis, Ind.), antibiotics, 2 mM
L-glutamine, and 5 × 10
5 M
2-mercaptoethanol. For in vitro induction of cytokines, duplicate suspensions of splenocytes were activated by the addition of 0.1 to 100 ng of MAM per ml, and supernatants were collected after 24 h of
incubation at 37°C in a 5% CO2 humidified incubator.
Supernatants were harvested, clarified by centrifugation at
500 × g for 10 min, and stored at 4°C until assayed
for specific cytokine content.
For in vivo priming studies, MAM at doses of 0.1 to 100 ng/mouse was
injected i.v. into BALB/c or C3H/HeJ mice. Control mice were given an
injection of phosphate-buffered saline (PBS) i.v.. After 90 min,
24 h, or 72 h, mice were bled by cardiac puncture, the sera
were collected for cytokine assays, and the splenocytes were cultured
in vitro in the presence or absence of MAM (0.4 ng/ml).
Determination of cytokine levels by ELISA.
Cytokines in test
supernatants were quantitated in duplicate wells by a capture
enzyme-linked immunosorbent assay (ELISA), using a modification of the
method of Schumacher et al. (57). Briefly, 100-µl portions
of cytokine-specific capture monoclonal antibodies (PharMingen, San
Diego, Calif.) were added to the wells of 96-well microtest plates at a
concentration of 1 to 4 µg/ml in the coating buffer solution (0.1 M
NaHCO3, pH 8.2). Following extensive washing and the
blocking of reactive sites on the plastic with PBS containing 20%
fetal calf serum, test supernatants and twofold serial dilutions of
appropriate reference cytokines (100 µl) were added. After an
overnight incubation and washing, 100-µl portions of the biotinylated
cytokine-specific detecting antibodies, at concentrations of 0.5 to 1 µg/ml, were also added to each well. The ELISA was developed with
avidin-conjugated horseradish peroxidase and
2,2'-azino-bis(3-ethylbenzthioline-6-sulfonic acid) (ABTS) substrate
(Sigma, St. Louis, Mo.). Optical density reading was performed at 405 nm with a model 3350-UV 96-well microtest plate spectrophotometer
(Bio-Rad, Hercules, Calif.). Cytokine concentrations are reported in
picograms per milliliter. The sensitivity for detection of these
cytokines was 15 to 30 pg/ml.
RT-PCR for the identification of IL-12 p40 mRNA.
RNA was
prepared by the method of Chomczynski and Sacchi (6), and
reverse transcription-PCR (RT-PCR) was performed as previously described by Mu et al. (49). PCR was carried out with a DNA thermal cycler 480 (Perkin-Elmer Cetus, Emeryville, Calif.). PCR conditions were as follows: denaturation, 94°C for 1 min; annealing, 59°C for 30 s; and elongation, 72°C for 30 s. Sixteen
cycles were performed for
-actin, and 28 cycles were performed for
IL-12 p40. Gene-specific sequences were derived from GenBank
submissions. The oligonucleotides used for these analyses have been
published previously (62).
Measurement of IgG2a and IgG1 levels in serum.
Sera were
obtained from mice at day 7 after injection of MAM. Immunoglobulin G2a
(IgG2a) and IgG1 were determined by ELISA on microtiter plates coated
with rat anti-mouse IgG2a and IgG1 (PharMingen) at a concentration of 2 µg/ml. Dilutions of serum were added to the wells, unbound sample was
washed off, and the amount of bound murine immunoglobulin was detected
by the addition of biotinylated IgG2a- or IgG1-specific antibodies, at
concentrations of 0.5 µg/ml, to each well. The ELISA was developed
and read as described above for cytokine assays. A simple linear
regression analysis of the immunoglobulin titration-generated reference
curve was used to extrapolate the amount of specific antibody contained in the test samples. These data are reported in micrograms per milliliter.
Induction and evaluation of arthritis induced by M. arthritidis.
M. arthritidis strain 14124P10 (29)
was grown in modified Edward broth medium consisting of
pleuropneumonialike organism broth (Difco Laboratories, Detroit, Mich.)
supplemented with 15% heat inactivated horse serum, 2.5% yeast
extract (Gibco BRL, Grand Island, N.Y.), 0.2% L-arginine
HCl, and 500 U of penicillin G (16) per ml, and harvested by
centrifugation at 27,000 × g for 30 minutes. After
washing in Difco broth alone, the organisms were resuspended in PBS
containing 5% sterile sucrose. Suspensions were frozen at
70°C,
and an aliquot was thawed and quantified for CFU. Female BALB/c and
C3H/HeJ mice, 8 to 10 weeks of age, were injected i.v. in groups of six
with 1 × 108 or 2 × 107 cfu of
M. arthritidis. Mice were examined for severity of arthritis from 3 to 28 days postinjection. Ankles and wrists were each scored from 0 to 4, and metatarsals and digits or metacarpals and digits also
received combined scores of 0 to 4 per extremity. The total maximal
score per mouse was 32. The results were expressed as means ± standard errors of the means (SEM).
Statistical analysis.
Concentrations of cytokines and
immunoglobulins are shown as means ± SEM. Student's t
test was performed using the Statview program (BrainPower, Inc.,
Calabasas, Calif.). A P value of less than 0.05 was
considered significant. Analysis of variance was used to determine the
significance of differences between mouse strain susceptibilities to
arthritis induced by M. arthritidis.
 |
RESULTS |
Influence of mouse strain on in vitro cytokine responses to
MAM.
Previous studies had suggested that BALB/c mice were more
resistant to arthritis induced by M. arthritidis than were
C3H mice. Since both of these strains give a high proliferative
response to MAM due to presence of H-2E
and possess a full
complement of MAM-reactive TCRs, dose-response experiments were
conducted in vitro to compare cytokine responses to MAM. Normal
splenocytes from BALB/c and C3H/HeJ mice were stimulated with MAM (0.1 to 100 ng/ml) for 24 h, and supernatants were assayed for
representative type 1 (IL-2, IFN-
, and TNF-
) and type 2 (IL-6 and
IL-10) cytokines. The results given in Fig.
1 show that activated splenocytes from BALB/c and C3H/HeJ mice produce similar levels and profiles of all
cytokines following 24 h of in vitro activation, irrespective of
dose. Cytokines were detectable with doses of as low as 0.1 ng of
MAM/ml and were maximal at 10 to 100 ng/ml. We next conducted experiments to determine whether in vivo differences between these strains in their response to MAM might relate to previous findings on
susceptibility to M. arthritidis-induced arthritis.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of different doses of MAM on cytokine
responses in BALB/c and C3H/HeJ mice in vitro. Splenocytes
(107 cells/ml) from BALB/c and C3H/HeJ strain mice were
stimulated with or without various concentrations of MAM. Twenty-four
hours later, culture supernatants were collected and analyzed by
capture ELISA for IL-2, IFN- , TNF- , IL-10, and IL-6. Data were
pooled from three experiments; splenocytes from two or three mice were
included in each experiment for each specific dose point, and results
are expressed as means ± SEM.
|
|
Early serum cytokine levels in response to MAM in vivo.
BALB/c
and C3H/HeJ mice were injected i.v. with MAM at doses of 1, 10, or 100 ng or with PBS. After 90 min, the mice were exsanguinated and the sera
were collected for assays. The cytokines IL-2, IL-4, IL-6, IL-10,
IFN-
, and TNF-
were assayed as described in Materials and Methods.
As expected, mice injected with PBS failed to produce significant
levels of serum cytokines (Fig. 2).
Furthermore, supernatants from splenocytes that were collected 90 min
after injection and incubated for 24 h in the absence of inducer
were also free of detectable cytokines (data not shown). However, 90 min after injection of MAM, levels of all cytokines in serum were
greatly increased in a dose-dependant fashion (Fig. 2). Cytokines were
detectable following injection with as little as 1 ng of MAM/mouse.
Although BALB/c mice injected with 100 ng of MAM showed somewhat
elevated serum IL-2, IL-4, and IL-10 levels (P < 0.05)
in comparison with C3H/HeJ mice, the levels of IL-6 and IFN-
were
similar in the two strains. By 24 h, serum cytokine levels had
largely subsided (data not shown).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of different doses of MAM on serum cytokine
profiles induced by BALB/c and C3H/HeJ mice. Mice were injected i.v.
with MAM at doses of 100, 10, and 1 ng or with diluent PBS. After 90 min the mice were exsanguinated and the sera were collected for
cytokine assays for IL-2, -4, -6, and -10, IFN- , and TNF- . Sera
from 2 or 3 mice were assayed in each experiment for each specific dose
point. Similar results were seen in three repeat experiments. ND, not
done.
|
|
Inducible in vitro cytokines differ in different mouse strains
after in vivo exposure to MAM.
When splenocytes from MAM-injected
mice were rechallenged in vitro with a second dose of MAM (0.4 ng/ml),
there were striking differences in the inducible cytokine profiles
between C3H/HeJ and BALB/c mice (Fig. 3
and 4). These differences appeared to be
dependent upon the duration of in vivo exposure to MAM. Splenic cells
taken from both C3H/HeJ and BALB/c mice injected with MAM 90 min
previously and challenged in vitro showed some increase in IL-2,
IFN-
, and IL-6, but levels of TNF-
were largely unchanged compared with those in mice receiving PBS. In contrast, whereas the
levels of IL-4 and IL-10 were very low in C3H/HeJ supernatants, they
were markedly elevated in BALB/c supernatants (Fig. 3).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 3.
Cytokines induced by cells from MAM-injected mice at 90 min. Splenocytes (107 cells/ml) from mice injected with MAM
90 min previously (0.1 to 100 ng of MAM/mouse) were rechallenged in
vitro with a second dose of MAM (0.4 ng/ml) for an additional 24 h, and inducible cytokine profiles in C3H/HeJ and BALB/c mice were
examined. IL-2, IFN- , TNF- , and IL-4, -6, and -10 were analyzed
by ELISA. Data were pooled from three experiments; splenocytes from two
or three mice were included in each experiment for each specific dose
point, and results are expressed as means ± SEM.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Cytokines induced by cells from MAM-injected mice at
24 h. Splenocytes (107 cells/ml) from mice injected
with MAM 24 h previously (0.1 to 100 ng of MAM/mouse) were
rechallenged in vitro with a second dose of MAM (0.4 ng/ml) for an
additional 24 h, and inducible cytokine profiles in C3H/HeJ and
BALB/c mice were examined. IL-2, IFN- , TNF- , and IL-4, -6, and
-10 were analyzed by ELISA. Data were pooled from three experiments;
splenocytes from two or three mice were included in each experiment for
each specific dose point, and results are expressed as means ± SEM.
|
|
The most striking divergence in the abilities of BALB/c and C3H/HeJ
splenocytes to respond to MAM upon in vitro challenge occurred when the
splenocytes were harvested after 24 h (Fig. 4) or 72 h (Fig.
5) of exposure to MAM. Thus, with
increasing in vivo MAM doses, IL-2, IFN-
, and TNF-
levels in
C3H/HeJ cell supernatants were all elevated, whereas they were markedly
depressed or showed no increase in BALB/c supernatants. In contrast,
levels of IL-4, IL-6, and IL-10 were all markedly increased in BALB/c cell cultures but were decreased or remained low in C3H/HeJ
supernatants (P
0.05). Doses of as low as 1 ng of
MAM/mouse were usually sufficient to induce a profound change in
inducible cytokine profiles, but these changes were optimal with the
higher doses of MAM. The results indicate that MAM commits the cytokine
profile to a type 1-like response in C3H/HeJ mice but to a type 2-like
response in BALB/c mice.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 5.
Cytokines induced by cells from MAM-injected mice at
72 h. Splenocytes (107 cells/ml) from mice injected
with MAM 72 h previously (0.1 to 100 ng of MAM/mouse) were
rechallenged in vitro with a second dose of MAM (0.4 ng/ml) for an
additional 24 h, and inducible cytokine profiles in C3H/HeJ and
BALB/c mice were examined. IL-2, IFN- , and IL-4 and -10 were
analyzed by ELISA. Data were pooled from two experiments; splenocytes
from two or three mice were included in each experiment for each
specific dose point, and results are expressed as means ± SEM.
|
|
Elevation of IL-12 p40 product in serum and gene expression in
splenocytes in MAM-injected C3H/HeJ mice.
A large number of
reports have documented a key role for IL-12 in the induction of type 1 immune responses (2, 33, 40, 65). In view of the described
observations, we tested whether there were differences in IL-12 mRNA
expression or serum IL-12 protein in C3H/HeJ versus BALB/c mice after
injection of MAM.
Spleens were obtained from C3H/HeJ and BALB/c mice at 90 min and
6 h after injection of MAM (10 ng/mouse). Spleen fragments were
immediately frozen in liquid nitrogen, and mRNA was prepared for RT-PCR
analysis. Six hours after injection of 10 ng of MAM/mouse, much less
IL-12 p40 mRNA was detectable, as analyzed by RT-PCR, in splenocytes of
BALB/c mice than in samples obtained from C3H/HeJ mice receiving same
dose of MAM (P < 0.04) (Fig.
6). Additionally, 90 min after injection
of MAM (10 ng/mouse), serum IL-12 levels, as determined by ELISA for
IL-12 p40, were greatly elevated in both BALB/c and C3H/HeJ mice
(P = 0.1). However, 12 h after injection of MAM,
serum IL-12 p40 remained high in C3H/HeJ mice injected with 10 ng of
MAM/mouse as compared to IL-12 levels in BALB/c mice receiving the same
treatment (P < 0.05) (Table
1).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 6.
In vivo IL-12 expression induced by MAM in BALB/c and
C3H/HeJ mice. RT-PCR was performed with mRNA isolated from homogenized
spleens obtained from mice 90 min and 6 h after injection with 10 ng of MAM/mouse or with PBS (not shown). Ratios of IL-12 p40 to
-actin densitometric values are included. The PCR data are
representative of two experiments.
|
|
MAM enhances the IgG2a response in C3H/HeJ mice but not BALB/c
mice.
Cytokines play a very important role in immunoglobulin
isotype selection in vitro and in vivo (25). In the mouse,
IL-4 preferentially augments IgG1 and IgE antibodies, whereas IFN-
preferentially induces switching to IgG2a and IgG3 antibodies.
Hence, IgG2a was used as a marker for type 1 responses induced by MAM,
while the titers of IgG1 reflect type 2 responses. The expression of
IgG isotypes (Fig. 7) in both mouse
strains after injection of MAM was assessed. Total IgG1 and IgG2a
concentrations were measured over a period of 33 days after injection
of MAM. Serum IgG1 levels increased slightly in response to MAM, but
there was no significant difference between the two mouse strains.
However, the total IgG2a response of mice injected with MAM was
significantly higher in C3H/HeJ mice than in BALB/c mice from day 7 (Fig. 7), and this difference was present through day 33 (data not
shown), when the experiment was terminated.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 7.
MAM greatly enhances IgG2a responses in C3H/HeJ
mice but not BALB/c mice. Serum samples were collected from mice of
both strains 7 days after injection with 1 or 10 ng of MAM/mouse or
with PBS. IgG2a and IgG1 isotypes in serum samples from BALB/c mice and
C3H/HeJ mice were measured by ELISA. The results shown are pooled data
from two separate experiments, each consisting of two or three animals
per group. Values are expressed as means ± SEM.
|
|
Susceptibility of BALB/c and C3H/HeJ mice to arthritis induced by
M. arthritidis.
Because of the potential genetic drift of
mouse strains tested many years previously for susceptibility to
arthritis induced by mycoplasmas, we repeated the earlier observations
using BALB/c and C3H/HeJ mice of the same age and source as those that
were used for determination of the cytokine responses to MAM. Arthritis scores obtained after an i.v. injection of 108 CFU of
M. arthritidis/mouse over a 1-month period are shown in Fig.
8. Disease severity was significantly
greater at all time periods in C3H/HeJ mice than in BALB/c mice
(P
0.02), although the incidence of arthritis was
100% in both groups. Disease onset was also more rapid and persisted
longer in the C3H/HeJ group. Mice given lower doses of organisms
(2 × 107/mouse) exhibited similar differences in
disease severity (data not shown), with only 33% of BALB/c mice
developing arthritis (mean maximum score of 0.3) and a 100% incidence
in the C3H/HeJ group (mean maximum score of 4.5). Thus, C3H/HeJ mice
remain significantly more susceptible to arthritis induced by M. arthritidis than BALB/c mice.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 8.
Susceptibility of BALB/c and C3H/HeJ mice to M. arthritidis. Mice were injected i.v. with 108 CFU of
M. arthritidis and scored for arthritis as described in
Materials and Methods through 28 days. Mean scores and SEM for BALB/c
( ) and C3H/HeJ ( ) mice are shown. C3H/HeJ mice were significantly
more susceptible at all time periods (P < 0.002).
|
|
 |
DISCUSSION |
SAgs are known to modify host immune systems and are increasingly
thought to play a role in both infectious and autoimmune diseases
(38, 56, 64). Three main findings have arisen from the
present studies. First, in vitro cytokine profiles induced by the
mycoplasma SAg MAM in splenocyte cultures from different strains of
mice do not predict their in vivo effects. Second, the in vivo cytokine
profile in response to MAM differs in different strains of mice, and
the patterns exhibit a distinct time dependency. Third, there is an
association between susceptibility to arthritis induced by M. arthritidis and the type of cytokine profile elicited in vivo by
its SAg MAM. Thus, the arthritis-susceptible C3H/HeJ mouse produces a
type 1 inflammatory cytokine response to MAM, whereas the
arthritis-resistant BALB/c mouse produces an arthritis-protective type
2 profile in response to MAM.
We and others (3, 7, 52, 53) have previously shown that MAM
induces diverse cell types to produce a wide variety of cytokines in
vitro. In the present studies, both type 1 (IL-2, IFN-
, and TNF-
)
and type 2 (IL-4, IL-6, and IL-10) cytokines were induced in 24-h
murine splenic cell cultures by using MAM concentrations from 0.1 to
100 ng/ml. Neither the cytokine profiles nor the relative levels of
each cytokine produced differed between BALB/c and C3H/HeJ mice.
Maximum levels were obtained with 10 to 100 ng of MAM per ml, and
50% of the maximal response occurred at about 1 ng/ml. These results
were in striking contrast to the data from subsequent in vivo studies.
Importantly, we observed a pronounced time-dependent polarization of
the cytokine profiles in C3H/HeJ versus BALB/c mice in response to the
in vivo administration of a single dose of MAM of as low as 1 ng/mouse.
The change in profiles with time likely reflects the change from an
early innate to an adaptive immune response. Cytokines were rapidly
produced and measurable in sera reflecting the early macrophage, NK
cell, and B- and T-cell responses. The two mouse strains were not
markedly different in this early response, although levels of the type
2 cytokines IL-4 and IL-10 were somewhat higher in the sera from BALB/c
mice. Splenocytes removed from BALB/c mice at 90 min and challenged in
vitro with MAM were also beginning to show an increase in type 2 cytokines, but type 1 cytokines IL-2, IFN-
, and TNF-
did not
differ from the response seen with cells from C3H/HeJ mice. Following
24 and 72 h of in vivo exposure to MAM, splenocytes from the two
mouse strains exhibited totally divergent cytokine profiles following rechallenge with MAM in vitro. BALB/c cells secreted elevated levels of
type 2 cytokines and depressed levels of type 1 cytokines, whereas the
reverse was true for C3H/HeJ cells. The early finding of elevated IL-12
in the sera and IL-12 mRNA in splenocytes from MAM-injected C3H/HeJ
mice suggests an important role for this cytokine in mediating the
profile differences observed in the adaptive responses. IL-12 is known
to promote clonal expansion of Th1 cells (65), and the
decreased level of this cytokine in BALB/c cells may at least
contribute to the overall type 2 profile seen in this mouse
strain in response to MAM. The persisting increased levels of IgG2a in
the sera of C3H/HeJ mice are also consistent with the development of a
type 1 cytokine profile in these mice.
A key question is why the cytokine profiles induced by MAM in
vivo differ in C3H/HeJ versus BALB/c mice. Different mouse strains are
known to elicit diverse cytokine responses to various microbial products. Whereas infection by Listeria monocytogenes
results in a type 1 response in susceptible C3H/HeJ mice, a type 2 response is seen in resistant BALB/c mice (33).
Leishmania major likewise elicits a type 2 response in
BALB/c mice but a type 1 response in C57BL/6 mice (59).
Evidence that the BALB/c mouse is not a "type 2 mouse" per se comes
from the observation that whole Bordetella pertussis
organisms elicit a type 1 response in this strain, while pertussis
toxin results in a mixed response (44, 49, 60). In addition,
Mycobacterium bovis bacillus Calmette Guérin (BCG)
also induces a predominantly type 1 cytokine response in BALB/c mice
(37, 66). Although it could be argued that contaminating LPS
might be responsible for the differences in response between the
LPS-resistant C3H/HeJ and LPS-susceptible BALB/c mice, it should be
noted that M. arthritidis does not possess LPS
(61) and that all nMAM preparations used here failed to induce a cytokine response in splenocyte cultures from MAM-refractory mouse strains. Differences in genetic background affecting such factors
as glucocorticoid hormones (21, 42) can also profoundly affect cytokine profiles. Thus, these hormones are down-regulated in
BALB/c mice infected with L. monocytogenes, changing the
cytokine profile to a type 1 response, whereas up-regulation of
glucocorticoids in the infected C3H/HeJ mouse promotes a type 2 cytokine response (30). For MAM, the pathways leading to
differential cytokine expression remain to be identified.
What are the implications of our observations for understanding the
role of SAgs in disease, particularly that induced by M. arthritidis? The striking difference in cytokine profiles elicited by MAM in arthritis-resistant versus susceptible mouse strains suggests
that the type 1 inflammatory cytokine profile seen with MAM in
vivo in the arthritis-susceptible C3H/HeJ mouse may also be
influencing M. arthritidis-induced joint disease. Arthritis in this strain was more severe and of longer duration than that in the
BALB/c mouse, which produced a type 2 protective cytokine profile in
response to injection with MAM. Although the mechanism(s) determining
the susceptibility or resistance to M. arthritidis-induced disease in different mouse strains is not fully understood, it is well
known that type 1 cytokines such as IL-2, IFN-
, and TNF-
can be
associated with acute inflammation. Pathologic reactions may also
result from defective cross-regulation by IL-4, IL-10, or other
cytokines that normally inhibit type 1 effector functions (58,
68).
In the present study, doses of MAM (10 to 100ng/mouse) which
induce a maximal cytokine response in vivo did not induce a significant toxic effect, and clinical arthritis failed to result from i.v. injection of these doses. The apparent inability of MAM alone to cause
arthritis and the production of MAM by avirulent strains of M. arthritidis (14) indicate that other factors also
influence disease expression. Our present finding that two highly
MAM-responsive mouse strains exhibit different degrees of
susceptibility to M. arthritidis supports this view. Rat
arthritis induced by M. arthritidis is in part dependent
upon the expression of certain adhesins (69), and the
virulence of arthritogenic strains is also associated in rats with a
newly discovered lysogenic virus (67). Membranes of the
organism contain leukocyte-activating components distinct from MAM
(B. C. Cole et al., unpublished observations). Recently, potent
lipoprotein macrophage-activating components have been identified in
Mycoplasma fermentans (50). It is likely,
therefore, that an interplay between these components and MAM as well
as the host genetic factors determines the ultimate outcome of
infection with this organism.
An excessive or uncontrolled type 1 cytokine response is known to occur
in a number of autoimmune diseases, such as rheumatoid arthritis,
insulin-dependent diabetes mellitus, and multiple sclerosis (39,
45, 54). There is increasing evidence for a role of SAgs in
triggering these conditions (56). In fact, studies from our
laboratory have clearly established that MAM can trigger and cause
flares in collagen-induced arthritis of mice (12), and type
1 cytokines are known to be elevated in this model of arthritis as well
(43). Our present finding that MAM also induces a similar type 1 cytokine response in mouse strains that are susceptible to
mycoplasma-induced arthritis combined with our recent finding of
antibodies to MAM in the sera from rheumatoid arthritis patients (55) further points to the value of the M. arthritidis model for human rheumatoid arthritis.
Although much of the work on the mechanisms of SAg action has
been conducted with mice using the staphylococcal SAgs, particularly staphylococcal enterotoxin B (SEB), several findings presented here and
elsewhere lead us to believe that the MAM SAg provides certain
advantages for these studies. First, MAM is produced by an organism
that naturally infects rodents, resulting in a variety of syndromes,
including arthritis. Also, MAM is much more potent for murine cells
than are the staphylococcal SAgs, and on the basis of the present and
previous data (4), amounts of MAM which might be expected to
be produced in the host by the organisms have been shown to profoundly
affect immune functions in vivo. It is attractive to speculate that
changes in the cytokine profiles as seen in the C3H/HeJ and BALB/c mice
may play a significant role not only in the disease manifestations of
M. arthritidis arthritis but also in other natural diseases
for which SAg involvement has been hypothesized. Our current studies
are directed toward further defining the interaction of MAM with the
murine immune system with a view to eventually understanding how SAgs
determine polarization of the adaptive immune response.
 |
ACKNOWLEDGMENTS |
We thank William Sewell and Janice Weiss for their critical and
useful comments on this manuscript. We thank Tamara Knappenberger and
Xiao-Dong Li for their technical assistance.
We acknowledge the support of the DNA synthesis facility by grant
CA42014 from the National Cancer Institute. This work was supported by
grant AR-02255 from the National Institute of Arthritis and
Musculoskeletal Diseases, by grant AI-12103 from the National Institute
of Allergy and Infectious Diseases, by a grant from the Nora Eccles
Treadwell Foundation, and by a grant from the Vallois Egbert
Foundation. B.C.C. is the recipient of the Nora Eccles Harrison Chair
in Rheumatology.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Rheumatology, Department of Internal Medicine, University of Utah
School of Medicine, 50 N. Medical Dr., Salt Lake City, UT 84132. Phone: (801) 581-8845. Fax: (801) 581-6069. E-mail for Hong-Hua Mu:
hong.mu{at}m.cc.utah.edu. E-mail for Barry C. Cole:
barry.cole{at}hsc.utah.edu.
Editor:
J. D. Clements
 |
REFERENCES |
| 1.
|
Acha-Orbea, H., and E. Palmer.
1991.
Mls a retrovirus exploits the immune system.
Immunol. Today
12:356-361[CrossRef][Medline].
|
| 2.
|
Afonso, L. C.,
T. M. Scharton,
L. Q. Vieira,
M. Wysocka,
G. Trinchieri, and P. Scott.
1994.
The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
Science
263:235-237[Abstract/Free Full Text].
|
| 3.
|
al-Daccak, R.,
K. Mehindate,
J. Hebert,
L. Rink,
S. Mecheri, and W. Mourad.
1994.
Mycoplasma arthritidis-derived superantigen induces proinflammatory monokine gene expression in the THP-1 human monocytic cell line.
Infect. Immun.
62:2409-2416[Abstract/Free Full Text].
|
| 4.
|
Atkin, C. L.,
S. Wei, and B. C. Cole.
1994.
The Mycoplasma arthritidis superantigen MAM: purification and identification of an active peptide.
Infect. Immun.
62:5367-5375[Abstract/Free Full Text].
|
| 5.
|
Choi, Y.,
J. W. Kappler, and P. Marrack.
1991.
A superantigen encoded in the open reading frame of the 3' long terminal repeat of mouse mammary tumour virus.
Nature (London).
350:203-207[CrossRef][Medline].
|
| 6.
|
Chomczynski, P., and N. Sacchi.
1987.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 7.
|
Cole, B. C.,
E. Ahmed,
B. A. Araneo,
J. Shelby,
C. Kamerath,
S. Wei,
S. McCall, and C. L. Atkin.
1993.
Immunomodulation in vivo by the Mycoplasma arthritidis superantigen, MAM.
Clin. Infect. Dis.
17:S163-S169.
|
| 8.
|
Cole, B. C.,
B. A. Araneo, and G. J. Sullivan.
1986.
Stimulation of mouse lymphocytes by a mitogen derived from Mycoplasma arthritidis. IV. Murine T hybridoma cells exhibit differential accessory cell requirements for activation by M. arthritidis T cell mitogen, concanavalin A, or egg-white lysozyme.
J. Immunol.
136:3572-3578[Abstract].
|
| 9.
|
Cole, B. C., and C. L. Atkin.
1991.
The Mycoplasma arthritidis T-cell mitogen, MAM: a model superantigen.
Immunol. Today
12:271-276[CrossRef][Medline].
|
| 10.
|
Cole, B. C.,
C. S. David,
D. H. Lynch, and D. R. Kartchner.
1990.
The use of transfected fibroblasts and transgenic mice establishes that stimulation of T cells by the Mycoplasma arthritidis mitogen is mediated by E .
J. Immunol.
144:420-424[Abstract].
|
| 11.
|
Cole, B. C.,
R. A. Daynes, and J. R. Ward.
1981.
Stimulation of mouse lymphocytes by a mitogen derived from Mycoplasma arthritidis. I. Transformation is associated with an H-2-linked gene that maps to the I-E/I-C subregion.
J. Immunol.
127:1931-1936[Abstract].
|
| 12.
|
Cole, B. C., and M. M. Griffiths.
1993.
Triggering and exacerbation of autoimmune arthritis by the Mycoplasma arthritidis superantigen MAM.
Arthritis Rheum.
36:994-1002[Medline].
|
| 13.
|
Cole, B. C.,
D. R. Kartchner, and D. J. Wells.
1989.
Stimulation of mouse lymphocytes by a mitogen derived from Mycoplasma arthritidis. VII. Responsiveness is associated with expression of a product(s) of the V 8 gene family present on the T cell receptor / for antigen.
J. Immunol.
142:4131-4137[Abstract].
|
| 14.
|
Cole, B. C.,
K. L. Knudtson,
A. Oliphant,
A. D. Sawitzke,
A. Pole,
M. Manohar,
L. S. Benson,
E. Ahmed, and C. L. Atkin.
1996.
The sequence of the Mycoplasma arthritidis superantigen, MAM: identification of functional domains and comparison with microbial superantigens and plant lectin mitogens.
J. Exp. Med.
183:1105-1110[Abstract/Free Full Text].
|
| 15.
|
Cole, B. C.,
A. D. Sawitzke,
E. A. Ahmed,
C. L. Atkin, and C. S. David.
1997.
Allelic polymorphisms at the H-2A and HLA-DQ loci influence the response of murine lymphocytes to the Mycoplasma arthritidis superantigen MAM.
Infect. Immun.
65:4190-4198[Abstract].
|
| 16.
|
Cole, B. C.,
R. N. Thorpe,
L. A. Hassell, and J. R. Ward.
1983.
Toxicity but not arthritogenicity of Mycoplasma arthritidis for mice associates with the haplotype expressed at the major histocompatibility complex.
Infect. Immun.
41:1010-1015[Abstract/Free Full Text].
|
| 17.
|
Cole, B. C.,
J. R. Ward, and L. Golightly-Rowland.
1973.
Factors influencing the susceptibility of mice to Mycoplasma arthritidis.
Infect. Immun.
7:218-225[Abstract/Free Full Text].
|
| 18.
|
Cole, B. C.,
L. R. Washburn, and D. Taylor-Robinson.
1985.
Mycoplasma induced arthritis, p. 107-160.
In
S. Razin, and M. F. Bairle (ed.), The Mycoplasmas, vol. 4. Academic Press, New York, N.Y.
|
| 19.
|
Cole, B. C., and D. J. Wells.
1990.
Immunosuppressive properties of the Mycoplasma arthritidis T-cell mitogen in vivo: inhibition of proliferative responses to T-cell mitogens.
Infect. Immun.
58:228-236[Abstract/Free Full Text].
|
| 20.
|
Crow, M. K.,
G. Zagon,
Z. Chu,
B. Ravina,
J. R. Tumang,
B. C. Cole, and S. M. Friedman.
1992.
Human B cell differentiation induced by microbial superantigens: unselected peripheral blood lymphocytes secrete polyclonal immunoglobulin in response to Mycoplasma arthritidis mitogen.
Autoimmunity.
14:23-32[Medline].
|
| 21.
|
Daynes, R.,
B. Araneo,
J. Hennebold,
E. Enioutina, and H. Mu.
1995.
Steroids as essential regulators of the mammalian immune response.
J. Invest. Dermatol.
105:14S-19S[CrossRef][Medline].
|
| 22.
|
Dellabona, P.,
J. Peccoud,
J. Kappler,
P. Marrack,
C. Benoist, and D. Mathis.
1990.
Superantigens interact with MHC class II molecules outside of the antigen groove.
Cell
62:1115-1121[CrossRef][Medline].
|
| 23.
|
Dietz, J. N., and B. C. Cole.
1982.
Direct activation of the J774.1 murine macrophage cell line by Mycoplasma arthritidis.
Infect. Immun.
37:811-819[Abstract/Free Full Text].
|
| 24.
|
D'Orazio, J. A.,
B. C. Cole, and J. Stein-Streilein.
1996.
Mycoplasma arthritidis mitogen up-regulates human NK cell activity.
Infect. Immun.
64:441-447[Abstract].
|
| 25.
|
Finkelman, F. D.,
J. Holmes,
I. M. Katona,
J. F. Urban, Jr.,
M. P. Beckmann,
L. S. Park,
K. A. Schooley,
R. L. Coffman,
T. R. Mosmann, and W. E. Paul.
1990.
Lymphokine control of in vivo immunoglobulin isotype selection.
Annu. Rev. Immunol.
8:303-333[CrossRef][Medline].
|
| 26.
|
Fiorentino, D. F.,
M. W. Bond, and T. R. Mosmann.
1989.
Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.
J. Exp. Med.
170:2081-2095[Abstract/Free Full Text].
|
| 27.
|
Fleischer, B.
1991.
Stimulation of human T cells by microbial `superantigens'.
Immunol. Res.
10:349-355[Medline].
|
| 28.
|
Florquin, S.,
A. Amraoui, and M. Goldman.
1996.
Persistent production of TH2-type cytokines and polyclonal B cell activation after chronic administration of staphylococcal enterotoxin B in mice.
J. Autoimmun.
9:609-615[CrossRef][Medline].
|
| 29.
|
Golightly-Rowland, L.,
B. C. Cole,
J. R. Ward, and B. B. Wiley.
1970.
Effect of animal passage on arthritogenic and biological properties of Mycoplasma arthritidis.
Infect. Immun.
1:538-545[Abstract/Free Full Text].
|
| 30.
|
Hennebold, J. D.,
H. H. Mu,
M. E. Poynter,
X. P. Chen, and R. A. Daynes.
1997.
Active catabolism of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase in vivo is a necessary requirement for natural resistance to infection with Listeria monocytogenes.
Int. Immunol.
9:105-115[Abstract/Free Full Text].
|
| 31.
|
Herman, A.,
J. W. Kappler,
P. Marrack, and A. M. Pullen.
1991.
Superantigens: mechanism of T-cell stimulation and role in immune responses.
Annu. Rev. Immunol.
9:745-772[Medline].
|
| 32.
|
Hodtsev, A. S.,
Y. Choi,
E. Spanopoulou, and D. Posnett.
1998.
Mycoplasma superantigen is a CDR3-dependent ligand for the T cell antigen receptor.
J. Exp. Med.
187:319-327[Abstract/Free Full Text].
|
| 33.
|
Hsieh, C. S.,
S. E. Macatonia,
C. S. Tripp,
S. F. Wolf,
A. O'Garra, and K. M. Murphy.
1993.
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages.
Science
260:547-549[Abstract/Free Full Text].
|
| 34.
|
Janeway, J., C. A.,
J. Yagi,
P. J. Conrad,
M. E. Katz,
B. Jones,
S. Vroegop, and S. Buxser.
1989.
T-cell responses to Mls and to bacterial proteins that mimic its behavior.
Immunol. Rev.
107:61-88[CrossRef][Medline].
|
| 35.
|
Kelso, A.
1995.
Th1 and Th2 subsets: paradigms lost?
Immunol. Today.
16:374-379[CrossRef][Medline].
|
| 36.
|
Lafon, M.
1993.
Rabies virus superantigen.
Res. Immunol.
144:209-213[CrossRef][Medline].
|
| 37.
|
Lagranderie, M. R. R.,
A.-M. Balazuc,
E. Deriaud,
C. D. Leclerc, and M. Gheorghiu.
1996.
Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains.
Infect. Immun.
64:1-9[Abstract].
|
| 38.
|
Leung, D. Y. M.,
B. T. Huber, and P. M. Schlievert (ed.).
1997.
Superantigens: molecular biology, immunology, and relevance to human disease.
Marcel Decker, Inc, New York, N.Y.
|
| 39.
|
Liblau, R.,
S. Singer, and H. McDevitt.
1995.
Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases.
Immunol. Today
16:34-38[CrossRef][Medline].
|
| 40.
|
Manetti, R.,
P. Parronchi,
M. Cuidizi, et al.
1993.
Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4 producing cells.
J. Exp. Med.
177:1199-1204[Abstract/Free Full Text].
|
| 41.
|
Marrack, P., and J. Kappler.
1990.
The staphylococcal enterotoxins and their relatives.
Science
248:705-711[Abstract/Free Full Text].
|
| 42.
|
Mason, D.,
I. MacPhee, and F. Antoni.
1990.
The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat.
Immunology
70:1[Medline].
|
| 43.
|
Mauri, C.,
R. O. Williams,
M. Walmsley, and M. Feldmann.
1996.
Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis.
Eur. J. Immunol.
26:1511-1518[Medline].
|
| 44.
|
Mills, K. H.,
M. Ryan,
E. Ryan, and B. P. Mahon.
1998.
A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.
Infect. Immun.
66:594-602[Abstract/Free Full Text].
|
| 45.
|
Miossec, P., and W. van den Berg.
1997.
Th1/Th2 cytokine balance in arthritis.
Arthritis Rheum.
40:2105-2115[Medline].
|
| 46.
|
Mosmann, T., and R. Coffman.
1989.
Heterogeneity of cytokine secretion patterns and functions of helper T cells.
Adv. Immunol.
46:111-147[Medline].
|
| 47.
|
Mosmann, T., and R. Coffman.
1989.
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.
Annu. Rev. Immunol.
7:145-173[CrossRef][Medline].
|
| 48.
|
Mourad, W.,
P. Scholl,
A. Diaz,
R. Geha, and T. Chatila.
1989.
The staphylococcal toxic shock syndrome toxin 1 triggers B cell proliferation and differentiation via major histocompatibility complex-unrestricted cognate T/B cell interaction.
J. Exp. Med.
170:2011-2022[Abstract/Free Full Text].
|
| 49.
|
Mu, H.-H., and W. A. Sewell.
1993.
Enhancement of interleukin-4 production of pertussis toxin.
Infect. Immun.
61:2834-2840[Abstract/Free Full Text].
|
| 50.
|
Muhlradt, P. F.,
M. Kiess,
H. Meyer,
R. Sussmuth, and G. Jung.
1997.
Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration.
J. Exp. Med.
185:1951-1958[Abstract/Free Full Text].
|
| 51.
|
Rincon, M.,
J. Anguita,
T. Nakamura,
E. Fikrig, and R. A. Flavell.
1997.
Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells.
J Exp Med.
185:461-9[Abstract/Free Full Text].
|
| 52.
|
Rink, L.,
W. Nicklas,
L. Alvarez Ossorio,
M. Koester, and H. Kirchner.
1994.
Differential induction of tumor necrosis factor alpha in murine and human leukocytes by Mycoplasma arthritidis-derived superantigen.
Infect. Immun.
62:462-467[Abstract/Free Full Text].
|
| 53.
|
Rink, L.,
W. Nicklas,
J. Luhm,
R. Kruse, and H. Kirchner.
1996.
Induction of a proinflammatory cytokine network by Mycoplasma arthritidis-derived superantigen (MAS).
J. Interferon Cytokine Res.
16:861-868[Medline].
|
| 54.
|
Romagnani, S.
1996.
Th1 and Th2 in human diseases.
Clin. Immunol. Immunopathol.
80:225-235[CrossRef][Medline].
|
| 55.
| Sawitzke, A. D., K. L. Knudtson, D. E. Joyner, H.-H. Mu, and B. C. Cole.Anti-MAM antibodies in
rheumatic disease: evidence for a MAM-like superantigen in rheumatoid
arthritis? J. Rheumatol., in press.
|
| 56.
|
Sawitzke, A. D.,
H. Mu, and B. Cole.
1999.
Superantigens and autoimmune disease: are they involved?
Curr. Opin. Infect. Dis.
12:213-219.
|
| 57.
|
Schumacher, J.,
S. O'Garra,
B. A. van Kimmenade,
M. Bond,
T. Mosmann, and R. Coffman.
1988.
The characterization of four monoclonal antibodies specific for mouse IL-5 and development of mouse and human IL-5 enzyme-linked immunosorbent.
J. Immunol.
141:1576[Abstract].
|
| 58.
|
Scott, B.,
R. Liblau,
S. Degermann,
L. Marconi,
L. Ogata,
A. Caton, et al.
1994.
A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity.
Immunity
1:1-20[CrossRef].
|
| 59.
|
Scott, P.,
E. Pearce,
A. W. Cheever,
R. L. Coffman, and A. Sher.
1989.
Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease.
Immunol Rev.
112:161-182[CrossRef][Medline].
|
| 60.
|
Sewell, W. A.,
P. A. de Mocrloose,
J. A. Hamilton,
J. W. Schrader,
I. R. Mackay, and M. A. Vadas.
1987.
Potentiation of delayed-type hypersensitivity by pertussigen or cyclophosphamide with release of different lymphokines.
Immunology
61:483-488[Medline].
|
| 61.
|
Smith, P.
1992.
Membrane lipid and polysaccharide structures, p. 79-91.
In
J. Maniloff (ed.), Mycoplasmas: molecular biology and pathogenesis. American Society for Microbiology, Washington, D.C.
|
| 62.
|
Spencer, N. F., and R. A. Daynes.
1997.
IL-12 directly stimulates expression of IL-10 by CD5+ B cells and IL-6 by both CD5+ and CD5 B cells: possible involvement in age-associated cytokine dysregulation.
Int. Immunol.
9:745-754[Abstract/Free Full Text].
|
| 63.
|
Tomai, M. A.,
J. A. Aelion,
M. E. Dockter,
G. Majumdar,
D. G. Spinella, and M. Kotb.
1991.
T cell receptor V gene usage by human T cells stimulated with superantigen streptococcal M protein.
J. Exp. Med.
174:285-288[Abstract/Free Full Text].
|
| 64.
|
Torres, B. A., and H. M. Johnson.
1998.
Modulation of disease by superantigens.
Curr. Opin. Immunol.
10:465-470[CrossRef][Medline].
|
| 65.
|
Trinchieri, G.
1995.
Interleukin 12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.
Annu. Rev. Immunol.
13:251-276[Medline].
|
| 66.
|
Tsicopoulos, A.,
Q. Hamid,
V. Varney,
S. Ying,
R. Moqbel,
S. R. Durham, and A. B. Kay.
1992.
Preferential messenger RNA expression of Th1-type cells (IFN-gamma+, IL-2+) in classical delayed-type (tuberculin) hypersensitivity reactions in human skin.
J. Immunol.
148:2058-2061[Abstract].
|
| 67.
|
Voelker, L.,
K. Weaver,
L. Ehle, and L. Washburn.
1995.
Association of lysogenic bacteriophage MAV1 with virulence of Mycoplasma arthritidis.
Infect Immun.
63:4016-4023[Abstract].
|
| 68.
|
von Herrath, M. G.,
S. Guerder,
H. Lewicki,
R. A. Flavell, and M. B. Oldstone.
1995.
Coexpression of B7-1 and viral ("self") transgenes in pancreatic beta cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes.
Immunity
3:727-738[CrossRef][Medline].
|
| 69.
|
Washburn, L. R., and E. J. Weaver.
1997.
Protection of rats against Mycoplasma arthritidis-induced arthritis by active and passive immunizations with two surface antigens.
Clin. Diagn. Lab. Immunol.
4:321-327[Abstract].
|
| 70.
|
White, J.,
A. Herman,
A. M. Pullen,
R. Kubo,
J. W. Kappler, and P. Marrack.
1989.
The V -specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice.
Cell
56:27-35[CrossRef][Medline].
|
Infection and Immunity, March 2000, p. 1142-1149, Vol. 68, No. 3
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bode, U., Lorchner, M., Pabst, R., Wonigeit, K., Overbeck, S., Rink, L., Hundrieser, J.
(2007). The superantigen-induced polarization of T cells in rat peripheral lymph nodes is influenced by genetic polymorphisms in the IL-4 and IL-6 gene clusters. Int Immunol
19: 81-92
[Abstract]
[Full Text]
-
Li, H., Van Vranken, S., Zhao, Y., Li, Z., Guo, Y., Eisele, L., Li, Y.
(2005). Crystal structures of T cell receptor {beta} chains related to rheumatoid arthritis. Protein Sci.
14: 3025-3038
[Abstract]
[Full Text]
-
Cole, B. C., Mu, H.-H., Pennock, N. D., Hasebe, A., Chan, F. V., Washburn, L. R., Peltier, M. R.
(2005). Isolation and Partial Purification of Macrophage- and Dendritic Cell-Activating Components from Mycoplasma arthritidis: Association with Organism Virulence and Involvement with Toll-Like Receptor 2. Infect. Immun.
73: 6039-6047
[Abstract]
[Full Text]
-
Rottem, S.
(2003). Interaction of Mycoplasmas With Host Cells. Physiol. Rev.
83: 417-432
[Abstract]
[Full Text]
-
Mu, H.-H., Sawitzke, A. D., Cole, B. C.
(2001). Presence of Lpsd Mutation Influences Cytokine Regulation In Vivo by the Mycoplasma arthritidis Mitogen Superantigen and Lethal Toxicity in Mice Infected with M. arthritidis. Infect. Immun.
69: 3837-3844
[Abstract]
[Full Text]
-
Hardy, R. D., Jafri, H. S., Olsen, K., Wordemann, M., Hatfield, J., Rogers, B. B., Patel, P., Duffy, L., Cassell, G., McCracken, G. H., Ramilo, O.
(2001). Elevated Cytokine and Chemokine Levels and Prolonged Pulmonary Airflow Resistance in a Murine Mycoplasma pneumoniae Pneumonia Model: a Microbiologic, Histologic, Immunologic, and Respiratory Plethysmographic Profile. Infect. Immun.
69: 3869-3876
[Abstract]
[Full Text]